Biotech
-
Bicara Therapeutics to Present at Goldman Sachs’ 46th Annual Global Healthcare Conference
Bicara Therapeutics (BCAX) will present at the Goldman Sachs 46th Annual Global Healthcare Conference. Management will host a fireside chat on June 10th to discuss the company’s strategy and pipeline. The presentation will focus on their clinical-stage bifunctional therapies, particularly their lead program, ficerafusp alfa, designed to treat solid tumors by overcoming challenges in the tumor microenvironment. A webcast replay will be available.
-
Defence Therapeutics Opens U.S. Lab in Boston-Cambridge Biotech Hub
Defense Therapeutics Inc. announced the opening of its first U.S. lab in the Boston-Cambridge area. This strategic move expands its R&D efforts within a leading biotech hub, focusing on the Accum® platform for antibody-drug conjugates (ADCs) used in cancer treatment. The Watertown facility provides access to crucial scientific resources and collaboration opportunities. Defense Therapeutics aims to establish a long-term presence in the area, aiming to strengthen its commitment to advancing their platform.
-
以下是几个可能的英文标题： * Taysha Gene Therapies Announces Pricing for Public Offering of Common Stock and Pre-Funded Warrants * Taysha Gene Therapies Sets Pricing for Public Offering of Common Stock and Pre-Funded Warrants * Taysha Gene Therapies Reveals Pricing of Public Offering for Common Stock and Pre-Funded Warrants
Taysha Gene Therapies (TSHA) announced a public offering to raise approximately $200 million. The offering includes common stock and pre-funded warrants, priced at $2.75 and $2.749 per share respectively. This capital will advance Taysha’s CNS-focused gene therapy programs, targeting diseases like Rett syndrome with its AAV-based therapies. The deal is expected to close around May 30, 2025.
